Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
This study has been terminated.
( Lack of enrollment )
Study NCT00343187 Information provided by Allergan
First Received: June 20, 2006 Last Updated: September 8, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Rash
Non-Small-Cell Lung Cancer
Additional conditions recognized in this trial
Carcinoma, Non-Small-Cell Lung
Exanthema
Lung Neoplasms
More general conditions related to this trial
Carcinoma
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Interventions listed in this trial
ACZONE (dapsone) Gel, 5%
Vehicle Control
Additional drug interventions recognized in this trial
Dapsone
Erlotinib
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antimalarials
Antiparasitic Agents
Antiprotozoal Agents
Enzyme Inhibitors
Folic Acid Antagonists
Leprostatic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Allergan
Back to top of Main Content
